PT Kalbe Farma Tbk. (PTKFF)

PT Kalbe Farma Tbk. (PTKFF) Healthcare & Pipeline Overview

PT Kalbe Farma Tbk. is an Indonesia-based healthcare company operating across prescription pharmaceuticals, consumer health, nutritionals, and distribution. With a diverse product portfolio including generic and branded drugs, OTC medicines, and specialized nutritional offerings, the company maintains a significant market presence throughout Indonesia, supported by its extensive distribution and logistics network.

What Is the Investment Thesis for PTKFF?

PT Kalbe Farma Tbk. (PTKFF) presents a compelling profile as an established Indonesian pharmaceutical leader, leveraging its extensive domestic presence and diversified business model across four core units: Prescription Pharmaceuticals, Consumer Health, Nutritionals, and Distribution and Logistic. The company's broad product portfolio, encompassing generic, branded, and licensed drugs, alongside OTC medicines and specialized nutritionals, positions it to capture growth across various healthcare segments within Indonesia. With a market capitalization of $2.03B, a P/E ratio of 9.07, and a robust profit margin of 10.0%, PTKFF demonstrates operational efficiency and profitability. Its gross margin stands at 38.7%, indicating strong control over production costs. The company also offers a dividend yield of 2.70%, providing income for investors. Key growth catalysts include the ongoing expansion of its nutritional offerings to cater to an aging population and specific medical needs, the increasing demand for contract research services from other pharmaceutical entities, and the continued development of its Mitrasana Clinics healthcare network. However, investors must consider the inherent risks associated with its OTC Other classification, including potential liquidity concerns and less stringent disclosure requirements. The company also faces ongoing challenges from increasing competition and the dynamic regulatory landscape within the Indonesian pharmaceutical industry.

Based on FMP financials and quantitative analysis

PTKFF Key Highlights

• Market Capitalization: $1.95 billion, reflecting its substantial presence in the Indonesian healthcare sector.
• Price-to-Earnings (P/E) Ratio: 9.07, indicating its valuation relative to earnings.
• Profit Margin: 10.0%, demonstrating the company's efficiency in converting revenue into net income.
• Gross Margin: 38.7%, highlighting strong profitability at the core product level before operating expenses.
• Dividend Yield: 2.70%, offering a return to shareholders from its earnings.
• Employee Base: 12,841 employees, underscoring its significant operational scale and workforce in Indonesia.

Who Are PTKFF's Competitors?

PTKFF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are PTKFF's Key Strengths?

• Established and extensive market presence throughout Indonesia since 1966.
• Highly diversified product portfolio across four core business units.
• Robust distribution and logistics network reaching various regions.
• Offers specialized contract services to other pharmaceutical companies.
• Operates a healthcare service network (Mitrasana Clinics) and provides health screening.
• Consistent dividend yield of 2.70%.

What Are PTKFF's Weaknesses?

• Trades on the OTC market, potentially implying less liquidity and transparency.
• Disclosure status is currently unknown, which can deter institutional investors.
• Reliance on the Indonesian market, potentially exposing it to country-specific economic or regulatory risks.
• Negative Beta of -0.04, suggesting low correlation with the broader market but also potentially lower sensitivity to market upturns.

What Could Drive PTKFF Stock Higher?

• **Ongoing:** Continuous expansion and innovation within its specialized nutritional product lines to meet evolving consumer health demands.
• **Ongoing:** Strategic development and growth of the Mitrasana Clinics healthcare service network, enhancing direct patient engagement and service offerings.
• **Ongoing:** Leveraging its robust distribution and logistics infrastructure to secure additional third-party contracts for consumer goods and medical equipment distribution across Indonesia.
• **Ongoing:** Further penetration into the animal health market through new product development or strategic partnerships, diversifying revenue streams.
• **Ongoing:** Increased demand for its contract services, including clinical study management and analytical services, from other pharmaceutical companies.

What Are the Key Risks for PTKFF?

• **Ongoing:** Risks associated with its OTC Other market classification, including potential liquidity issues and less stringent disclosure requirements.
• **Potential:** Adverse regulatory changes or policy shifts within the Indonesian pharmaceutical industry that could impact product approvals, pricing, or market access.
• **Ongoing:** Intensifying competition from both domestic and international pharmaceutical manufacturers, potentially eroding market share or profit margins.
• **Potential:** Fluctuations in raw material costs or supply chain disruptions affecting manufacturing expenses and product availability.
• **Potential:** Economic instability or currency depreciation in Indonesia, which could impact consumer purchasing power or the cost of imported goods.

What Are the Growth Opportunities for PTKFF?

• **Expansion of Nutritional Product Portfolio:** PT Kalbe Farma Tbk. has a significant opportunity to capitalize on the growing demand for specialized nutritional products across all age demographics and for specific medical conditions. With an aging global population and increasing health consciousness, the market for infant and toddler nutrition, adult supplements, and medical dietary requirements is expanding. By continuing to innovate and tailor offerings for expectant mothers, seniors, and individuals with particular health needs, the company can deepen its penetration in a market segment that values specialized health solutions. This ongoing focus allows PTKFF to capture a larger share of a market driven by demographic shifts and preventive health trends, with long-term growth potential.
• **Growth in Pharmaceutical Contract Services:** The firm's provision of contract services, including clinical study management, bioavailability/bioequivalence studies, and analytical services, represents a robust growth avenue. As pharmaceutical research and development costs escalate globally, many companies seek to outsource specialized services to optimize efficiency and leverage external expertise. PT Kalbe Farma Tbk., with its established infrastructure and scientific capabilities, is well-positioned to attract more third-party contracts. This segment offers a high-margin revenue stream that is less susceptible to direct consumer market fluctuations, providing a stable and expanding source of income by supporting the broader pharmaceutical industry's innovation pipeline.
• **Development of Healthcare Service Network:** The operation and expansion of the Mitrasana Clinics healthcare service network, coupled with health screening services, offers a direct engagement model with consumers and patients. As healthcare access and quality become increasingly important in Indonesia, developing a robust network of clinics can enhance brand loyalty, provide valuable patient data, and create a synergistic ecosystem with its pharmaceutical product sales. This direct service model allows PTKFF to capture a share of the healthcare services market, moving beyond just product manufacturing to integrated patient care. This strategy can lead to long-term revenue growth and strengthen its overall market position.
• **Diversification into Animal Health Products:** The animal health sector is a steadily growing market, driven by increasing pet ownership, rising awareness of animal welfare, and the economic importance of livestock. PT Kalbe Farma Tbk.'s existing pharmaceutical expertise and distribution capabilities provide a strong foundation for expanding its animal health product offerings. This diversification allows the company to tap into a distinct market segment with different demand drivers and regulatory considerations, reducing reliance on human pharmaceutical sales alone. By developing or acquiring new products for veterinary use, PTKFF can capture a share of this specialized market, contributing to overall revenue growth and portfolio resilience over the medium to long term.
• **Leveraging Distribution and Logistics Network:** PT Kalbe Farma Tbk.'s extensive Distribution and Logistic unit, which already handles various consumer goods, medical equipment, cosmetics, and other trade items, presents a significant opportunity for further expansion. By optimizing and expanding its third-party logistics services, the company can become a preferred partner for other businesses seeking efficient market access across Indonesia. This leverages existing infrastructure and expertise to generate additional revenue streams beyond its own product sales. As e-commerce and supply chain complexities increase, a reliable and widespread distribution network becomes an invaluable asset, positioning PTKFF for continued growth in logistics services.

What Opportunities Does PTKFF Have?

• Growing demand for specialized nutritional products across all age groups and medical needs.
• Increasing outsourcing trend for pharmaceutical R&D, boosting contract service demand.
• Expansion of its healthcare service network and health screening offerings.
• Diversification into the growing animal health product market.
• Leveraging its distribution network for third-party consumer goods and medical equipment.

What Threats Does PTKFF Face?

• Potential for adverse regulatory changes within the Indonesian pharmaceutical industry.
• Intensifying competition from both domestic and international pharmaceutical companies.
• Inherent risks associated with OTC market trading, including price volatility and limited information.
• Economic downturns or currency fluctuations in Indonesia impacting consumer spending and import costs.

What Are PTKFF's Competitive Advantages?

• **Established Market Presence:** Over five decades of operation in Indonesia have built strong brand recognition and trust among consumers and healthcare providers.
• **Extensive Distribution Network:** A robust and widespread distribution and logistics infrastructure ensures broad product availability across the diverse Indonesian archipelago.
• **Diversified Product Portfolio:** A wide range of products across prescription, consumer health, and nutritionals reduces reliance on single product lines and caters to varied market needs.
• **Integrated Business Model:** The combination of manufacturing, distribution, and healthcare services creates synergistic advantages and multiple revenue streams.
• **Contract Services Expertise:** Offering specialized clinical and analytical services positions the company as a valuable partner for other pharmaceutical entities.

What Does PTKFF Do?

Founded in 1966 and headquartered in Jakarta, Indonesia, PT Kalbe Farma Tbk. has evolved into a prominent pharmaceutical powerhouse within the Indonesian healthcare landscape. The company, along with its affiliated entities, is deeply engaged in the comprehensive development, manufacturing, and commercialization of a vast array of pharmaceutical products distributed nationwide. Its operational structure is segmented into four core business units: Prescription Pharmaceuticals, Consumer Health, Nutritionals, and Distribution and Logistic, enabling a multifaceted approach to the market. Within its Prescription Pharmaceuticals segment, PT Kalbe Farma Tbk. offers a diverse range of medications, encompassing generic, branded, and licensed drugs. Notable examples include Brainact, Cefspan, Mycoral, Cernevit, Cravit, Neuralgin, Broadced, Neurotam, Hemapo, and CPG. These critical medications are supplied to a wide network of hospitals, pharmacies, and drug retailers across Indonesia, ensuring broad access to essential treatments. The Consumer Health unit extends beyond prescription items, providing over-the-counter medicines, popular energy drinks, ready-to-consume beverages, various dietary supplements, and other preventive health products, addressing everyday wellness needs. The Nutritionals division is a cornerstone of the company's offerings, providing specialized nutritional products tailored for all life stages. This includes formulations for infants and toddlers, children, adolescents, adults, expectant and lactating mothers, and seniors. Furthermore, it caters to individuals with specific medical dietary requirements, highlighting a commitment to comprehensive health support. Beyond product manufacturing and sales, PT Kalbe Farma Tbk. offers crucial contract services to other pharmaceutical companies, encompassing clinical study management, bioavailability/bioequivalence studies, and analytical services, leveraging its expertise and infrastructure. The company's activities are further diversified to include animal health products and the operation of the Mitrasana Clinics, a healthcare service network providing direct patient care. Additionally, PT Kalbe Farma Tbk. offers health screening services, acts as an agent and representative for biotechnology products, and plays a significant role in distribution. Its distribution arm handles various consumer goods, medical equipment, cosmetics, and other trade items, demonstrating its robust logistical capabilities. The firm also trades in medical and laboratory apparatus and supplies, raw materials for pharmaceutical production, and consumable products essential for hemodialysis therapy, while also providing advertising services, solidifying its integrated market position.

What Products and Services Does PTKFF Offer?

• Develops, manufactures, and commercializes a broad range of pharmaceutical products across Indonesia.
• Offers prescription pharmaceuticals, including generic, branded, and licensed drugs, to hospitals, pharmacies, and retailers.
• Provides consumer health products such as over-the-counter medicines, energy drinks, and dietary supplements.
• Manufactures specialized nutritional offerings for all age groups and specific medical dietary requirements.
• Operates a robust Distribution and Logistic unit for its own products and third-party goods.
• Extends contract services to other pharmaceutical companies, covering clinical studies and analytical services.
• Supplies animal health products and manages the Mitrasana Clinics healthcare service network.
• Trades in medical/laboratory apparatus, pharmaceutical raw materials, and hemodialysis consumables.

How Does PTKFF Make Money?

• Generates revenue through the sale of a diverse portfolio of prescription and over-the-counter pharmaceutical products.
• Earns income from the manufacturing and distribution of nutritional products tailored for various demographics and medical needs.
• Provides fee-based contract services to other pharmaceutical companies, including clinical research and analytical testing.
• Leverages its extensive distribution network to generate revenue from logistics services for various consumer goods and medical equipment.
• Operates healthcare service networks like Mitrasana Clinics, offering health screening and direct patient care.

What Industry Does PTKFF Operate In?

PT Kalbe Farma Tbk. operates within Indonesia's dynamic and growing healthcare sector, specifically as a prominent player in the Drug Manufacturers - General industry. The company's strategic positioning is characterized by its comprehensive product offerings, spanning prescription pharmaceuticals, consumer health, and nutritionals, which allows it to address a wide spectrum of patient and consumer needs across the archipelago. This diversified approach helps mitigate risks associated with reliance on a single product category. The Indonesian pharmaceutical market is influenced by factors such as a large and expanding population, increasing health awareness, and government initiatives aimed at improving healthcare access. PTKFF's established presence and extensive distribution network provide a competitive advantage in reaching diverse geographic areas. However, the industry is also marked by increasing competition from both domestic and international players, alongside evolving regulatory frameworks that necessitate continuous adaptation and innovation to maintain market share and profitability.

Who Are PTKFF's Key Customers?

• Hospitals, pharmacies, and drug retailers for prescription and over-the-counter medications.
• General consumers seeking wellness products, energy drinks, and dietary supplements.
• Individuals across all age groups, from infants to seniors, requiring specialized nutritional products.
• Other pharmaceutical companies utilizing contract research, bioavailability, and analytical services.
• Patients accessing healthcare services through Mitrasana Clinics and health screening programs.

ROE 16%Key Financial Metrics

Return on equity for PT Kalbe Farma Tbk. stands at 15.6%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 11.3%, showing how much profit it generates from its asset base. PTKFF trades at a trailing price-to-earnings ratio of 9.57, below the Healthcare sector average of ~23x. Its free cash flow yield is 7.1%, a gauge of the cash the business throws off relative to its market value. A current ratio of 3.56 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 10.4%, the inverse of the P/E and a quick read on earnings relative to price.

PT Kalbe Farma Tbk. (PTKFF) Valuation Context

Valued at $2.03B, PTKFF is classified as a mid-cap stock. Relative to its peer group, PTKFF's quantitative score of 47/100 is below the peer average of 60/100.

Company Profile

PT Kalbe Farma Tbk. operates in the Drug Manufacturers - General industry within the Healthcare sector. It is headquartered in Jakarta, ID. The company is led by CEO Bernadette Ruth Irawati Setiady. PTKFF has traded publicly since 2002.

F-Score 6/9Financial Health

PT Kalbe Farma Tbk.'s Piotroski F-Score is 6/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 6.42 places it in the safe zone, indicating low near-term bankruptcy risk.

FY2026 estForward Outlook

Wall Street analysts project PT Kalbe Farma Tbk. revenue of about $35.03T for fiscal 2026, with EPS near $78.25. The estimate reflects 13 contributing analysts.

PTKFF Financials

PTKFF Latest News

No recent news available for PTKFF.

PTKFF Analyst Consensus

PTKFF MoonshotScore

What Investors Ask About PT Kalbe Farma Tbk. (PTKFF) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources